Impact Biomedicines

12526 High Bluff Drive, Suite 260
San Diego
United States

Tel: 858-221-0950


Show articles for this employer

About Impact Biomedicines

Impact Biomedicines is pioneering the development of life-changing treatments for patients with myeloproliferative neoplasms and other cancers. Led by a highly skilled and devoted team, Impact is advancing a late-stage pipeline centered around fedratinib, a potent and highly selective oral small molecule JAK2 kinase inhibitor, which is being developed initially for the treatment of myelofibrosis (MF) and polycythemia vera (PV). Impact was formed in 2016 after acquisition of Sanofi’s full rights for the global development and commercialization of fedratinib. The Impact team intends to pursue multiple clinical indications for fedratinib to maximize its potential as a best-in-class therapy for JAK2-dependent diseases.


Founder & CEO: Dr. John Hood
Co-Founder & Interim CMO: Dr. Catriona Jamieson
Co-Founder & CFO: Raghu Saripalli
President and CBO: Charles McDermott
Sr. VP, Commercial: Randy Adams
Sr. VP, Technical Operations: Jeff Barker

Currently, there are no jobs for this employer on BioSpace.

Browse jobs with BioSpace Featured Employers here.